

PROVIDER BULLETIN

PROVIDER INFORMATION



January 2, 2024

Medical Policy Updates: Coupe Health and Self-Funded Benefit Plans Managed by Blue Cross and Blue Shield of Alabama

Participating providers are invited to submit for consideration scientific, evidence-based information, professional consensus opinions, and other information supported by medical literature relevant to our draft policies for Coupe Health and Self-Funded benefit plans managed by Blue Cross and Blue Shield of Alabama.

The draft policies are available for physician comment for 45 days from the posting date found on the document. Make sure your voice is heard by providing feedback directly to us.

How to Submit Comments on Draft Medical Policies

[Complete our medical policy feedback form](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback) online at <https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback> or send comments and supporting documentation to us by mail or fax:

Birmingham Service Center
Attn: Health Management - Medical Policy
P.O. Box 10527
Birmingham, AL 35202
Fax: 205-220-0878

Draft Medical Policies

Draft medical policies can be found at [Policies & Guidelines \(exploremyplan.com\)](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback)

Policy #	Policy Title
MP-537	Peroral Endoscopic Myotomy (POEM) for Treatment of Esophageal Achalasia and Refractory Gastroparesis
MP-548	Identification of Microorganisms Using Nucleic Acid Probes
MP-557	Cardioverter Defibrillators: Wearable or External
MP-567	Biomarker Testing in Risk Assessment and Management of Cardiovascular Disease
MP-756	Sphenopalatine Ganglion Block for Headache
MP-757	Axillary Reverse Mapping for Prevention of Lymphedema

Draft Provider-Administered Drug Policies

Draft provider-administered drug policies can be found at [Policies & Guidelines \(exploremyplan.com\)](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback) and [Policies & Guidelines \(exploremyplan.com\)](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback)

Policy #	Policy Title
PH-90731	Pombiliti (cipaglucoasidase alfa-atga)

Policy #	Policy Title
VP-90598	Abecma (idecabtagene vicleucel)
VP-90590	Breyanzi (lisocabtagene maraleucel)
VP-90663	Carvykti (ciltacabtagene autoleucel)
PH-90202	Entyvio IV (vedolizumab)
VP-90319	Kymriah (tisagenlecleucel)
PH-90558	Tecartus (brexucabtagene autoleucel)
PH-90002	Tocilizumab IV (Actemra; Tofidence)
VP-90333	Yescarta (axicabtagene ciloleucel)